Posts With Tag biopharmaceutical sector

Explore Roivant Sciences' Q4 2024 financial performance, highlighting losses, asset sales, and a 'Hold' stock recommendation. Key insights on cash reserves and market strategy.

Explore scPharmaceuticals Inc.'s Amendment No. 1 on Form 10-Q/A revealing executive trading arrangements and regulatory updates. No financial changes noted.